{"protocolSection": {"identificationModule": {"nctId": "NCT02007278", "orgStudyIdInfo": {"id": "CLAF237ACO01"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride", "officialTitle": "Glycemic Excursions in Type 2 Diabetic Patients Treated With Vildagliptin and Metformin (GalvusMet) Versus Glimepiride and Metformin", "acronym": "GLOBE"}, "statusModule": {"statusVerifiedDate": "2017-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-01-03", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2016-02-22", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-02-22", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-12-05", "studyFirstSubmitQcDate": "2013-12-05", "studyFirstPostDateStruct": {"date": "2013-12-10", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-02-23", "resultsFirstSubmitQcDate": "2017-04-13", "resultsFirstPostDateStruct": {"date": "2017-07-11", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-04-13", "lastUpdatePostDateStruct": {"date": "2017-07-11", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of this study was to compare the effect of a fixed dose combination of vildagliptin plus metformin versus combination therapy of glimepiride plus metformin in glycemic variability in patients with type 2 diabetes who have not achieved adequate control of their disease prior to treatment with metformin monotherapy in optimal doses."}, "conditionsModule": {"conditions": ["Type 2 Diabetes", "Hypoglycemia"], "keywords": ["diabetes", "hypoglycemia", "glycemic variability", "vildagliptin", "glimepiride"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 40, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "vildagliptin and metformin", "type": "ACTIVE_COMPARATOR", "description": "Based on basal dose of metformin, administration of vildagliptin/metformin 50 mg/850 mg twice daily (bid) or 50 mg/1000 mg bid for 12 weeks", "interventionNames": ["Drug: vildagliptin and metformin (combination)"]}, {"label": "glimepiride and metformin", "type": "ACTIVE_COMPARATOR", "description": "Protocol specified dosage and frequency of glimepiride + metformin for 12 weeks based on basal dose of metformin", "interventionNames": ["Drug: glimepiride", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "vildagliptin and metformin (combination)", "description": "vildagliptin and metformin combination therapy as 50mg/850mg bid or 50mg/1000mg bid", "armGroupLabels": ["vildagliptin and metformin"]}, {"type": "DRUG", "name": "glimepiride", "armGroupLabels": ["glimepiride and metformin"]}, {"type": "DRUG", "name": "Metformin", "armGroupLabels": ["glimepiride and metformin"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Glycemic Variability Measured by Mean Amplitude of Glucose Excursions (MAGE)", "description": "Mean Amplitude of Glycemic Excursions (MAGE) , which determines the average blood glucose excursions either above or below a value of one standard deviation of the average value of glucose in a given day. MAGE is calculated from the data of continuous tissue glucose monitoring obtained during the measurement period. MAGE is calculated with the formula \u03a3 \u03bb / \u03c7 if \u03bb\\> \u03bd (where \u03bb = changes in blood glucose from peak to nadir, \u03c7 = number of valid observations, \u03bd = 1 standard deviation of the mean glucose during a period of 24 hours) from the data of continuous monitoring of the tissue glucose, obtained during the period of measurement.", "timeFrame": "Week 12"}], "secondaryOutcomes": [{"measure": "Glycemic Variability Measured by Continuous Overlapping Net Glycemic Action (CONGA)", "description": "Continuous Overlapping Net Glycemic Action (CONGA) which assesses intra-day glycemic variability by calculating the difference between values at different intervals, adjusted according to requirements with the advantage of being highly reproducible.\n\nCONGA is calculated in the conventional way with the formula \u221at\u049b\u03a3t = t1 (Dt -\u010e2) / \u049b - 1, \u010e = t\u049b \u03a3 Dt t = t1 / \u049b, Dt = Gt-Gt-m (where \u049b = Observations with an observation n x 60 minutes, G = glucose measure) from the data of continuous monitoring of tissue glucose obtained during the measurement period.", "timeFrame": "Week 12"}, {"measure": "Glycemic Variability Measured by Total Standard Deviation (TSD)", "description": "Total standard deviation (TSD) or standard deviation of all values of a given measurement period, which has the advantage of being able to include all measured values on a given time period (even several days) through a common and simple statistical concept.\n\nTSD is calculated conventionally with the formula \u03c3 = \u221a\u03a3 (Xi - \u1fe6) 2 / N (where Xi represents each of the values, \u1fe6 represents the population mean and N is the number of observations) from the data of continuous monitoring of tissue glucose obtained during the measurement.", "timeFrame": "Week 12"}, {"measure": "Percentage of Patients Who Achieved a Decrease Equal to or Greater Than 0.3% in Value of HbA1c at Week 12", "timeFrame": "Screening visit , 12 weeks of treatment"}, {"measure": "Change in HbA1c at Week 12 of Treatment in Comparison to HbA1c at Baseline", "timeFrame": "baseline, 12 weeks of treatment"}, {"measure": "Number of Patients With Incidence of Hypoglycemia", "description": "Hypoglycemia defined as Glycemia \\< 70 mg/dl", "timeFrame": "12 weeks"}, {"measure": "Mean Amplitude of Glycemic Excursions (MAGE) for Patients With Hypoglycemia Incidence After 12 Weeks of Treatment", "description": "MAGE , which determines the average blood glucose excursions either above or below a value of one standard deviation of the average value of glucose in a given day. MAGE is calculated from the data of continuous tissue glucose monitoring obtained during the measurement period. MAGE is calculated with the formula \u03a3 \u03bb / \u03c7 if \u03bb\\> \u03bd (where \u03bb = changes in blood glucose from peak to nadir, \u03c7 = number of valid observations, \u03bd = 1 standard deviation of the mean glucose during a period of 24 hours) from the data of continuous monitoring of the tissue glucose, obtained during the period of measurement. In this endpoint, mean MAGE value is reported for hypo glycemic patients.", "timeFrame": "12 weeks"}, {"measure": "Number of Patients With Any Adverse Events, Serious Adverse Events and Death", "timeFrame": "12 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Key Inclusion Criteria:\n\n* HbA1c between 8%-10.5% in stable metformin dose (\\>1500 mg/day), four weeks prior visit 1\n\nKey Exclusion Criteria:\n\n* Use of other antidiabetic oral therapy during the last 3 months (sulphonylurea, glitazones, GLP-1 analogues, DPP-4 inhibitors), except metformin", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Medell\u00edn", "state": "Antioquia", "country": "Colombia", "geoPoint": {"lat": 6.25184, "lon": -75.56359}}, {"facility": "Novartis Investigative Site", "city": "Manizales", "state": "Caldas", "zip": "1700", "country": "Colombia", "geoPoint": {"lat": 5.06889, "lon": -75.51738}}, {"facility": "Novartis Investigative Site", "city": "Bogot\u00e1", "state": "Cundinamarca", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "Novartis Investigative Site", "city": "Ch\u00eda", "state": "Cundinamarca", "zip": "11001000", "country": "Colombia", "geoPoint": {"lat": 4.85876, "lon": -74.05866}}, {"facility": "Novartis Investigative Site", "city": "Cali", "state": "Valle del Cauca", "zip": "760001", "country": "Colombia", "geoPoint": {"lat": 3.43722, "lon": -76.5225}}, {"facility": "Novartis Investigative Site", "city": "Bogot\u00e1", "zip": "00000", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "Novartis Investigative Site", "city": "Cali", "country": "Colombia", "geoPoint": {"lat": 3.43722, "lon": -76.5225}}, {"facility": "Novartis Investigative Site", "city": "Monteria", "country": "Colombia", "geoPoint": {"lat": 8.74798, "lon": -75.88143}}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A total of 9 research centers participated in the study, from which 76 patients were screened for inclusion and exclusion criteria, obtaining 40 patients eligible for randomization", "groups": [{"id": "FG000", "title": "Vildagliptin and Metformin", "description": "Based on basal dose of metformin, administration of vildagliptin/metformin 50 mg/850 mg twice daily (bid) or 50 mg/1000 mg bid for 12 weeks"}, {"id": "FG001", "title": "Glimepiride and Metformin", "description": "Protocol specified dosage and frequency of glimepiride + metformin for 12 weeks based on basal dose of metformin"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "20"}, {"groupId": "FG001", "numSubjects": "20"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "17"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Failure to comply with an eligibility", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Ingestion of drugs not allowed in study", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Incorrect medication administration", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Mis-randomization", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Randomized set", "groups": [{"id": "BG000", "title": "Vildagliptin and Metformin", "description": "Based on basal dose of metformin, administration of vildagliptin/metformin 50 mg/850 mg twice daily (bid) or 50 mg/1000 mg bid for 12 weeks"}, {"id": "BG001", "title": "Glimepiride and Metformin", "description": "Protocol specified dosage and frequency of glimepiride + metformin for 12 weeks based on basal dose of metformin"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "40"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "56.74", "spread": "10.58"}, {"groupId": "BG001", "value": "55.70", "spread": "11.51"}, {"groupId": "BG002", "value": "56.25", "spread": "10.92"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "23"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "17"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Glycemic Variability Measured by Mean Amplitude of Glucose Excursions (MAGE)", "description": "Mean Amplitude of Glycemic Excursions (MAGE) , which determines the average blood glucose excursions either above or below a value of one standard deviation of the average value of glucose in a given day. MAGE is calculated from the data of continuous tissue glucose monitoring obtained during the measurement period. MAGE is calculated with the formula \u03a3 \u03bb / \u03c7 if \u03bb\\> \u03bd (where \u03bb = changes in blood glucose from peak to nadir, \u03c7 = number of valid observations, \u03bd = 1 standard deviation of the mean glucose during a period of 24 hours) from the data of continuous monitoring of the tissue glucose, obtained during the period of measurement.", "populationDescription": "Analysis set includes all randomized patients excluding the ones who were prematurely withdrawn and the ones who have no data from visit 7 which required for comparison.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Vildagliptin and Metformin", "description": "Based on basal dose of metformin, administration of vildagliptin/metformin 50 mg/850 mg twice daily (bid) or 50 mg/1000 mg bid for 12 weeks"}, {"id": "OG001", "title": "Glimepiride and Metformin", "description": "Protocol specified dosage and frequency of glimepiride + metformin for 12 weeks based on basal dose of metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6.68", "spread": "1.48"}, {"groupId": "OG001", "value": "6.23", "spread": "1.08"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Power=95%; significance level=5%, characteristic operation curves were used with a non-central F distribution for the calculation of the sample size", "pValue": "0.4510", "statisticalMethod": "Wilcoxon (Mann-Whitney)"}]}, {"type": "SECONDARY", "title": "Glycemic Variability Measured by Continuous Overlapping Net Glycemic Action (CONGA)", "description": "Continuous Overlapping Net Glycemic Action (CONGA) which assesses intra-day glycemic variability by calculating the difference between values at different intervals, adjusted according to requirements with the advantage of being highly reproducible.\n\nCONGA is calculated in the conventional way with the formula \u221at\u049b\u03a3t = t1 (Dt -\u010e2) / \u049b - 1, \u010e = t\u049b \u03a3 Dt t = t1 / \u049b, Dt = Gt-Gt-m (where \u049b = Observations with an observation n x 60 minutes, G = glucose measure) from the data of continuous monitoring of tissue glucose obtained during the measurement period.", "populationDescription": "Analysis set includes all randomized patients excluding the ones who were prematurely withdrawn and the ones who have no data from visit 7 which required for comparison.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Vildagliptin and Metformin", "description": "Based on basal dose of metformin, administration of vildagliptin/metformin 50 mg/850 mg twice daily (bid) or 50 mg/1000 mg bid for 12 weeks"}, {"id": "OG001", "title": "Glimepiride and Metformin", "description": "Protocol specified dosage and frequency of glimepiride + metformin for 12 weeks based on basal dose of metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.92", "spread": "0.93"}, {"groupId": "OG001", "value": "3.01", "spread": "1.10"}]}]}]}, {"type": "SECONDARY", "title": "Glycemic Variability Measured by Total Standard Deviation (TSD)", "description": "Total standard deviation (TSD) or standard deviation of all values of a given measurement period, which has the advantage of being able to include all measured values on a given time period (even several days) through a common and simple statistical concept.\n\nTSD is calculated conventionally with the formula \u03c3 = \u221a\u03a3 (Xi - \u1fe6) 2 / N (where Xi represents each of the values, \u1fe6 represents the population mean and N is the number of observations) from the data of continuous monitoring of tissue glucose obtained during the measurement.", "populationDescription": "Analysis set includes all randomized patients excluding the ones who were prematurely withdrawn and the ones who have no data from visit 7 which required for comparison.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Week 12", "groups": [{"id": "OG000", "title": "Vildagliptin and Metformin", "description": "Based on basal dose of metformin, administration of vildagliptin/metformin 50 mg/850 mg twice daily (bid) or 50 mg/1000 mg bid for 12 weeks"}, {"id": "OG001", "title": "Glimepiride and Metformin", "description": "Protocol specified dosage and frequency of glimepiride + metformin for 12 weeks based on basal dose of metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.36", "spread": "0.40"}, {"groupId": "OG001", "value": "1.40", "spread": "0.42"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Who Achieved a Decrease Equal to or Greater Than 0.3% in Value of HbA1c at Week 12", "populationDescription": "Analysis set includes all randomized patients excluding the ones who were prematurely withdrawn and the ones who have confirmed non-concordant data", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of patients", "timeFrame": "Screening visit , 12 weeks of treatment", "groups": [{"id": "OG000", "title": "Vildagliptin and Metformin", "description": "Based on basal dose of metformin, administration of vildagliptin/metformin 50 mg/850 mg twice daily (bid) or 50 mg/1000 mg bid for 12 weeks"}, {"id": "OG001", "title": "Glimepiride and Metformin", "description": "Protocol specified dosage and frequency of glimepiride + metformin for 12 weeks based on basal dose of metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "17"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "100.0"}, {"groupId": "OG001", "value": "100.0"}]}]}]}, {"type": "SECONDARY", "title": "Change in HbA1c at Week 12 of Treatment in Comparison to HbA1c at Baseline", "populationDescription": "Analysis set includes all randomized patients excluding the ones who were prematurely withdrawn and the ones who have confirmed non-concordant data", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of glycosylated haemoglobin", "timeFrame": "baseline, 12 weeks of treatment", "groups": [{"id": "OG000", "title": "Vildagliptin and Metformin", "description": "Based on basal dose of metformin, administration of vildagliptin/metformin 50 mg/850 mg twice daily (bid) or 50 mg/1000 mg bid for 12 weeks"}, {"id": "OG001", "title": "Glimepiride and Metformin", "description": "Protocol specified dosage and frequency of glimepiride + metformin for 12 weeks based on basal dose of metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "17"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.92", "spread": "1.1"}, {"groupId": "OG001", "value": "2.28", "spread": "0.79"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With Incidence of Hypoglycemia", "description": "Hypoglycemia defined as Glycemia \\< 70 mg/dl", "populationDescription": "Analysis set includes all randomized patients excluding the ones who were prematurely withdrawn and the ones who have no data from visit 7 which required for comparison.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Patients", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Vildagliptin and Metformin", "description": "Based on basal dose of metformin, administration of vildagliptin/metformin 50 mg/850 mg twice daily (bid) or 50 mg/1000 mg bid for 12 weeks"}, {"id": "OG001", "title": "Glimepiride and Metformin", "description": "Protocol specified dosage and frequency of glimepiride + metformin for 12 weeks based on basal dose of metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "4"}]}]}]}, {"type": "SECONDARY", "title": "Mean Amplitude of Glycemic Excursions (MAGE) for Patients With Hypoglycemia Incidence After 12 Weeks of Treatment", "description": "MAGE , which determines the average blood glucose excursions either above or below a value of one standard deviation of the average value of glucose in a given day. MAGE is calculated from the data of continuous tissue glucose monitoring obtained during the measurement period. MAGE is calculated with the formula \u03a3 \u03bb / \u03c7 if \u03bb\\> \u03bd (where \u03bb = changes in blood glucose from peak to nadir, \u03c7 = number of valid observations, \u03bd = 1 standard deviation of the mean glucose during a period of 24 hours) from the data of continuous monitoring of the tissue glucose, obtained during the period of measurement. In this endpoint, mean MAGE value is reported for hypo glycemic patients.", "populationDescription": "Analysis set includes all randomized patients excluding the ones who were prematurely withdrawn and the ones who have no data from visit 7 which required for comparison and had at least one hypoglycemia event.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Vildagliptin and Metformin", "description": "Based on basal dose of metformin, administration of vildagliptin/metformin 50 mg/850 mg twice daily (bid) or 50 mg/1000 mg bid for 12 weeks"}, {"id": "OG001", "title": "Glimepiride and Metformin", "description": "Protocol specified dosage and frequency of glimepiride + metformin for 12 weeks based on basal dose of metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "4"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.23", "spread": "NA", "comment": "Standard deviation is not measurable for one patient"}, {"groupId": "OG001", "value": "5.53", "spread": "0.82"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With Any Adverse Events, Serious Adverse Events and Death", "populationDescription": "All the randomized patients.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Patients", "timeFrame": "12 weeks", "groups": [{"id": "OG000", "title": "Vildagliptin and Metformin", "description": "Based on basal dose of metformin, administration of vildagliptin/metformin 50 mg/850 mg twice daily (bid) or 50 mg/1000 mg bid for 12 weeks"}, {"id": "OG001", "title": "Glimepiride and Metformin", "description": "Protocol specified dosage and frequency of glimepiride + metformin for 12 weeks based on basal dose of metformin"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "20"}]}], "classes": [{"title": "Any adverse events (serious and non-serious)", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "13"}]}]}, {"title": "Serious Adverse Events", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}, {"title": "Death", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "eventGroups": [{"id": "EG000", "title": "Vildagliptin and Metformin", "description": "Based on basal dose of metformin, administration of vildagliptin/metformin 50 mg/850 mg twice daily (bid) or 50 mg/1000 mg bid for 12 weeks", "seriousNumAffected": 0, "seriousNumAtRisk": 20, "otherNumAffected": 9, "otherNumAtRisk": 20}, {"id": "EG001", "title": "Glimepiride and Metformin", "description": "Protocol specified dosage and frequency of glimepiride + metformin for 12 weeks based on basal dose of metformin", "seriousNumAffected": 1, "seriousNumAtRisk": 20, "otherNumAffected": 13, "otherNumAtRisk": 20}], "seriousEvents": [{"term": "Erysipelas", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}], "otherEvents": [{"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Ear pain", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "Vertigo", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Eye irritation", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "Eyelid oedema", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Presbyopia", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Refraction disorder", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Hypothermia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "Influenza like illness", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Oedema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Jaundice", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "Hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Chikungunya virus infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Onychomycosis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Tinea pedis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Tooth abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Bone fissure", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Limb injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Soft tissue injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "Wound", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Blood pressure increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 20}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "Costochondritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Joint crepitation", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Musculoskeletal pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Neck pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 20}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Hypoaesthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 20}]}, {"term": "Tremor", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 20}]}, {"term": "Urine abnormality", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Pleuritic pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Respiratory distress", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Respiratory tract congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Hyperhidrosis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 20}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Rash maculo-papular", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 20}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 20}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "email": "trialandresults.registries@novartis.com", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000007003", "term": "Hypoglycemia"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "relevance": "LOW"}, {"id": "M10053", "name": "Hypoglycemia", "asFound": "Hypoglycemia", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000057619", "term": "Glimepiride"}, {"id": "D000077597", "term": "Vildagliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000007166", "term": "Immunosuppressive Agents"}, {"id": "D000007155", "term": "Immunologic Factors"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M1857", "name": "Vildagliptin", "asFound": "100%", "relevance": "HIGH"}, {"id": "M252104", "name": "Glimepiride", "asFound": "Bioequivalence", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}